Arab & Middle East News
(ARABNEWSWIRE.COM, July 06, 2017 ) Recently there has been a substantial growth in the vaccine market with the rising incidences of cancer & HIV cases. World Health Organization growth estimations indicate the market may increase in value to almost 54.5 billion 2020, with the arrival of new therapeutic preventive, and adult vaccines.
Full report at: http://www.marketdataforecast.com/market-reports/europe-preventive-vaccine-market-142/
The vaccine Market is quite different from any other product market, having distinct features with increased complexity of assessing, understanding prices and procurement. Although it is a small market compared to the pharmaceutical market, we cannot dismiss the fact that it is growing at a fast rate. There are currently around 120 new vaccines in the pipeline of various multinational companies across the world and are set to hit the market in the coming years. While the vaccine market is rather concentrated on both supply and demand sides, it is mostly dependent on public purchasers and donor policies.
Introduction of new vaccines for every other diseases is aiding the growth of vaccine market. Also, rise in the frequency of occurrence of infectious diseases like tuberculosis, hepatitis, diphtheria and pneumococcal diseases across the globe has increased the usage of vaccines. Invested from governments for vaccine development, increase in funding by the major market players, rising occurrence of disease, technological advancements decreasing the new vaccine development time drastically, initiatives by NGO’s are some of the factors that are propelling the growth of vaccines However, there are few factors restraining the growth of vaccine market like, huge capital expenditures and stringent regulatory policies by the governments, massive cost associated with treatment.
The Europe Preventive Vaccines Market is segmented by type of vaccine as Live, attenuated vaccines, inactivated vaccines, Toxoid vaccines, Subunit vaccines, Conjugate vaccines, DNA vaccines and Recombinant vector vaccines. In addition, based on age groups the market is categorized as Paediatric Vaccine (Pneumococcal, MMR, Varicella, Hepatitis, Poliovirus, HIB and others) and Adult vaccines (Influenza, Cervical Cancer, Hepatitis, Zoster and others). Furthermore, on the basis of geography, the European Market is analysed under various regions namely, UK, Spain, Italy, Germany and France.
Historically many of the multinational vaccine companies have been investing huge sums in research and development resulting in new innovations in the market. The major players in the preventive vaccine market are GlaxoSmithKline, plc, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast